SLC’s senior management brings decades of pharmaceutical development, quality management, and production management experience from working at the largest international biopharmaceutical companies.

Management

M. Sherry Ku, Ph. D|Chairman & CEO

Dr. Ku was the Head of Early Pharmaceutical Development at Wyeth/Lederle (now Pfizer), overseeing discovery interface through clinical proof of concept. During her 20-year tenure, she oversaw new drug development for over 170 new clinical leads resulting in 85 original NME IND filings. She also developed 8 commercial products including Suprax, Zosyn/Tazocin, Zebeta, Isovorin, Thioplex, Sonata, Tygacil and Bosulif, three of which are antibiotics. Zosyn, in particular, remains as one of the three lifesaving injectable antibiotics in the hospital worldwide. She was in charge of a penem facility and has early exposure to carbapenems via participation in the development of Biapenem with Lederle Japan/Takeda. Sherry often leads the effort in New Drug Application and is responsible for FDA PAI activities. In 2009, Dr. Ku joined TWi Pharma as their Chief Scientific Officer and President, filing 6 high barrier ANDAs and establishing a pipeline of 6 new drugs which included 3 biologic drugs. In 2012 she co-founded Ruen Huei Biopharmaceutical Company and served as the company’s President. In 2014 Sherry Ku was elected Chairman of the Board of Savior Lifetec Corporation and also serves as the Chief Executive Officer.

Dr. Ku received her B.S. in Pharmaceutical Chemistry from National Taiwan University. She then earned a Ph.D. in Pharmaceutical Chemistry at the Ohio State University.

 

S.H. Pan, Ph. D|Chief Technology Officer

Dr. Pan joined Merck in 1977, focusing on biochemical process research and development and commercialization. At Merck, Dr. Pan served as both the company’s Director of Technical Operations and the Director of Pharmaceutical Engineering when Imipenem was developed at the time. In 2005, Dr. Pan joined Genentech as the Senior Director of Biologics Process Engineering, designing the technologies for monoclonal antibodies processing and dosage filling as well as the facility and system engineering market expansion. In 2010, Dr. Pan went to Bristol Meyer’s Squibb and served as both the Executive Director of Process Development and Head of Global Manufacturing Sciences and Technology, where he designed the cold chain/cryogenic strategy and validation of formulated bulk logistics. In his time at Merck, Genentech, and Bristol Meyer’s Squibb, Dr. Pan commercialized 10 processes and launched 6 manufacturing facilities. In 2013, Dr. Pan joined Savior Lifetec Corporation, and now serves as the Chief Technology Officer.

Dr. Pan received his B.S. in Chemical Engineering from National Taiwan University. He then earned a Ph.D. in Chemistry at the University of Washington.